CTC BIO
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
CTC BIO makes medicines and health products for both animals and humans, ranging from digestive enzyme treatments to film-dissolving oral doses and combination drug formulations.
Its products are used across veterinary and human healthcare, and it supplies both the domestic South Korean market and international markets. Listed on KOSDAQ, Korea's tech and small-cap board, the company carries a portfolio of hundreds of distinct products, meaning no single item dominates its revenue.
Summary is AI-generated and may contain errors · figures from DART filings
CTC BIO holds proprietary core technologies including microbial fermentation, drug coating, and drug-delivery systems that underpin its in-house product development across both its animal and human medicine divisions.
CTC BIO in five facts
What does CTC BIO do?
CTC BIO makes medicines and health products for both animals and humans, ranging from digestive enzyme treatments to film-dissolving oral doses and combination drug formulations.
Where is CTC BIO listed and in which sector?
CTC BIO (Korean name: 씨티씨바이오) trades under KRX code 060590 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is CTC BIO?
Its market capitalisation was US$51.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were CTC BIO's latest annual revenue and operating profit?
For fiscal year 2025, CTC BIO reported revenue of US$93.4M, operating profit of US$4.7M and net income of US$2.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 14.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.